Survival trends and patient characteristics between 2004 and 2016 for breast cancer in Japan based on the National Clinical Database-Breast Cancer Registry
Breast Cancer. 2024 Feb 6. doi: 10.1007/s12282-024-01545-x. Online ahead of print.ABSTRACTThis is a prognostic report by the Japanese Breast Cancer Society on breast cancer extracted from the National Clinical Database-Breast Cancer Registry of Japan. Here, we present a summary of 457,878 breast cancer cases registered between 2004 and 2016. The median follow-up duration was 5.6 years. The median age at the start of treatment was 59 years (5-95%: 38-82 years) and increased from 57 years between 2004 and 2008 to 60 years between 2013 and 2016. The proportion of patients with Stage 0-II disease increased from 74.5% to 78.3%. The number of cases with estrogen and progesterone receptor positivity increased from 74.8% to 77.9% and 60.5% to 68.1%, respectively. Regarding (neo-)adjuvant chemotherapy, the taxane (T) or taxane-cyclophosphamide (C) regimen increased by 2.4% to 8.2%, but the (fluorouracil (F)) adriamycin (A)-C-T/(F) epirubicin (E)C-T and (F)AC/(F)EC regimens decreased by 18.6% to 15.2% and 13.5% to 5.0%, respectively. Regarding (neo-)adjuvant anti-human epidermal growth factor-2 (HER2)-targeted therapy, the use of trastuzumab increased from 4.6% to 10.5%. The rate of sentinel lymph node biopsy increased from 37.1% to 60.7%, while that of axillary dissection decreased from 54.5% to 22.6%. Improvements in disease-free and overall survival were observed in patients with HER2-positive breast cancer, but there was no apparent trend in patients with hormone receptor-positive,...
Source: Breast Cancer - Category: Cancer & Oncology Authors: Takayuki Iwamoto Hiraku Kumamaru Naoki Niikura Yasuaki Sagara Minoru Miyashita Takaaki Konishi Naoko Sanuki Kenta Tanakura Masayuki Nagahashi Naoki Hayashi Masayuki Yoshida Chie Watanabe Naoko Kinukawa Masakazu Toi Shigehira Saji Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | HER2 | Herceptin | Hormones | Japan Health